$LSTA
LISATA THERAPEUTICS, INC.

2012 Q1 Form 8-K Financial Statement

#000144530512002656 Filed on August 15, 2012

View on sec.gov

Income Statement

Concept 2012 Q1 2011 2010 Q4
Revenue $3.773M $10.05M $18.11M
YoY Change -80.74% 5448.06% 58.72%
Cost Of Revenue $2.956M $8.647M $14.65M
YoY Change -79.3% 52.45%
Gross Profit $817.0K $1.403M $3.450M
YoY Change -84.63% 674.73% 92.74%
Gross Profit Margin 21.66% 13.96% 19.05%
Selling, General & Admin $6.412M $27.69M $7.900M
YoY Change -33.45% 42.22% -35.19%
% of Gross Profit 784.83% 1972.86% 228.99%
Research & Development $1.947M $7.721M $2.570M
YoY Change -29.33% 28.5% 48.55%
% of Gross Profit 238.33% 550.15% 74.49%
Depreciation & Amortization $390.0K $900.0K $2.580M
YoY Change -82.27% 350.0% 316.13%
% of Gross Profit 47.73% 64.13% 74.78%
Operating Expenses $8.359M $35.41M $10.48M
YoY Change -32.53% 36.0% -24.71%
Operating Profit -$7.542M -$34.00M -$7.030M
YoY Change 6.6% 31.53% -42.04%
Interest Expense $524.1K $2.648M -$460.0K
YoY Change -38.5% 814.49%
% of Operating Profit
Other Income/Expense, Net -$436.7K -$561.8K $480.0K
YoY Change -60.4% -1374.41% -4900.0%
Pretax Income -$7.979M -$34.57M -$7.000M
YoY Change -2.44% 33.93% -42.29%
Income Tax $0.00 $0.00 -$640.0K
% Of Pretax Income
Net Earnings -$9.348M -$47.13M -$6.180M
YoY Change -8.11% 102.24% -50.12%
Net Earnings / Revenue -247.78% -469.0% -34.12%
Basic Earnings Per Share
Diluted Earnings Per Share -$8.348M -$52.96M -$10.66M
COMMON SHARES
Basic Shares Outstanding 114.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2012 Q1 2011 2010 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.80M $3.900M $15.60M
YoY Change 131.91% -75.0% 110.81%
Cash & Equivalents $7.005M $3.900M $8.469M
Short-Term Investments $0.00
Other Short-Term Assets $2.800M $33.00M $4.400M
YoY Change 1584.72% 650.0% -21.43%
Inventory $17.98M $600.0K $0.00
Prepaid Expenses
Receivables $10.44M $1.000M $28.21K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $52.98M $38.60M $46.88M
YoY Change 5.11% -17.7% 47.43%
LONG-TERM ASSETS
Property, Plant & Equipment $47.33M $11.60M $435.5K
YoY Change 302.62% -68.65% -97.96%
Goodwill $19.67M $0.00
YoY Change 180.41% -100.0%
Intangibles $36.27M $563.4K
YoY Change 536.38%
Long-Term Investments
YoY Change
Other Assets $6.164M $78.90M $2.798M
YoY Change 959.36% 2620.69% 1299.04%
Total Long-Term Assets $114.3M $116.7M $96.14M
YoY Change -8.84% 21.44% 21.24%
TOTAL ASSETS
Total Short-Term Assets $52.98M $38.60M $46.88M
Total Long-Term Assets $114.3M $116.7M $96.14M
Total Assets $167.3M $155.3M $143.0M
YoY Change -4.84% 8.6% 28.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.40M $2.300M $595.5K
YoY Change 56.41% -83.92% -92.82%
Accrued Expenses $3.430M $1.100M $720.4K
YoY Change -16.33% -50.0% -34.51%
Deferred Revenue
YoY Change
Short-Term Debt $19.40M $3.600M $3.000M
YoY Change 312.77% 20.0% 36.36%
Long-Term Debt Due $300.0K $100.0K $9.600M
YoY Change -97.96% -98.96% -2.04%
Total Short-Term Liabilities $47.14M $36.40M $32.89M
YoY Change 15.25% 10.98% 30.52%
LONG-TERM LIABILITIES
Long-Term Debt $4.200M $4.800M $6.500M
YoY Change -34.38% -26.15% -52.55%
Other Long-Term Liabilities $25.00M $30.20M $11.20M
YoY Change 4525.35% 169.64% 49.33%
Total Long-Term Liabilities $34.19M $35.00M $17.11M
YoY Change 6225.46% 97.74% -19.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $47.14M $36.40M $32.89M
Total Long-Term Liabilities $34.19M $35.00M $17.11M
Total Liabilities $81.32M $93.30M $50.00M
YoY Change -26.6% -1.17% -42.65%
SHAREHOLDERS EQUITY
Retained Earnings -$152.6M -$95.32M
YoY Change
Common Stock $129.9K $63.81K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $63.37M $62.00M $48.66M
YoY Change
Total Liabilities & Shareholders Equity $167.3M $155.3M $143.0M
YoY Change -4.84% 8.6% 28.74%

Cashflow Statement

Concept 2012 Q1 2011 2010 Q4
OPERATING ACTIVITIES
Net Income -$9.348M -$47.13M -$6.180M
YoY Change -8.11% 102.24% -50.12%
Depreciation, Depletion And Amortization $390.0K $900.0K $2.580M
YoY Change -82.27% 350.0% 316.13%
Cash From Operating Activities $2.106M -$20.93M -$5.300M
YoY Change -120.66% 146.89% -564.91%
INVESTING ACTIVITIES
Capital Expenditures $132.0K $574.9K -$3.870M
YoY Change -81.34% -47.52% 127.65%
Acquisitions
YoY Change
Other Investing Activities $20.00K -$1.480M -$2.220M
YoY Change -100.83% 102.74% 2675.0%
Cash From Investing Activities -$110.1K -$2.055M -$6.090M
YoY Change -96.45% -87.99% 242.13%
FINANCING ACTIVITIES
Cash Dividend Paid $0.00
YoY Change -100.0%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $7.185M $20.07M 22.87M
YoY Change 1.48% -40.72% 1055.05%
NET CHANGE
Cash From Operating Activities $2.106M -$20.93M -5.300M
Cash From Investing Activities -$110.1K -$2.055M -6.090M
Cash From Financing Activities $7.185M $20.07M 22.87M
Net Change In Cash $9.182M -$2.913M 11.48M
YoY Change -247.64% -135.21% 756.72%
FREE CASH FLOW
Cash From Operating Activities $2.106M -$20.93M -$5.300M
Capital Expenditures $132.0K $574.9K -$3.870M
Free Cash Flow $1.974M -$21.50M -$1.430M
YoY Change -118.11% 124.64% -150.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2010Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2393000 USD
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3917400 USD
CY2011Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
1177100 USD
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2287201 USD
CY2010Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
595547 USD
CY2011Q1 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
1370900 USD
CY2011Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
451400 USD
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1010475 USD
CY2010Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
28206 USD
CY2010Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
720423 USD
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1090176 USD
CY2010Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
720400 USD
CY2011Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
1090200 USD
CY2011Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
-1268000 USD
CY2010Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
-369100 USD
CY2010Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
2800000 USD
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
4200000 USD
CY2010Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2779066 USD
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4152343 USD
CY2011Q4 us-gaap Acquired Finite Lived Intangible Asset Amount
AcquiredFiniteLivedIntangibleAssetAmount
5700000 USD
CY2011 us-gaap Additional Information About Entitys Reportable Segments
AdditionalInformationAboutEntitysReportableSegments
three reportable segments
CY2010Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
141137522 USD
CY2011Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
200858638 USD
CY2010 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
567700 USD
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2791100 USD
CY2010Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
39536 USD
CY2011Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
334400 USD
CY2011 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2440241 USD
CY2010 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
281211 USD
CY2011 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
577300 USD
CY2010 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
35200 USD
CY2011Q4 us-gaap Assets
Assets
155327780 USD
CY2010Q4 us-gaap Assets
Assets
143024749 USD
CY2011Q4 us-gaap Assets Current
AssetsCurrent
38610336 USD
CY2010Q4 us-gaap Assets Current
AssetsCurrent
46882845 USD
CY2010Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
38062981 USD
CY2011Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
32367217 USD
CY2011Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Noncurrent
AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
75570645 USD
CY2010Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Noncurrent
AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
92344963 USD
CY2011Q4 us-gaap Business Acquisition Contingent Consideration At Fair Value
BusinessAcquisitionContingentConsiderationAtFairValue
70000 USD
CY2010Q4 us-gaap Business Acquisition Contingent Consideration At Fair Value Noncurrent
BusinessAcquisitionContingentConsiderationAtFairValueNoncurrent
0 USD
CY2011Q4 us-gaap Business Acquisition Contingent Consideration At Fair Value Noncurrent
BusinessAcquisitionContingentConsiderationAtFairValueNoncurrent
3130000 USD
CY2011Q4 us-gaap Cash
Cash
791100 USD
CY2011Q4 us-gaap Cash
Cash
92900 USD
CY2011Q1 us-gaap Cash
Cash
227900 USD
CY2010 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 USD
CY2011 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
320863 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3935160 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8469123 USD
CY2009Q4 us-gaap Cash And Cash Equivalents At Carrying Value Including Discontinued Operations
CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations
7159369 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value Including Discontinued Operations
CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations
15612391 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value Including Discontinued Operations
CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations
12745432 USD
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2866959 USD
CY2010 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8453022 USD
CY2010 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
576601 USD
CY2011 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
2739496 USD
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109329587 shares
CY2010Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64221130 shares
CY2010Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64221130 shares
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109329587 shares
CY2010 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-13510432 USD
CY2011 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-1803182 USD
CY2010 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
10200364 USD
CY2011 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
845206 USD
CY2011Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
37389825 shares
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2010Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2010Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
109330 USD
CY2010Q4 us-gaap Common Stock Value
CommonStockValue
63813 USD
CY2010 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21826046 USD
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45761192 USD
CY2010 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
5264600 USD
CY2011 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-8224678 USD
CY2011 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-53985870 USD
CY2010 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-16561446 USD
CY2011 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
CY2010 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
13720048 USD
CY2011 us-gaap Conversion Of Stock New Issuance
ConversionOfStockNewIssuance
164418
CY2010Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1 shares
CY2011Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1 shares
CY2011 us-gaap Cost Of Revenue
CostOfRevenue
8646687 USD
CY2010 us-gaap Cost Of Revenue
CostOfRevenue
0 USD
CY2010Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
-80000 USD
CY2011Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
-5596600 USD
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1121134 USD
CY2010Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
59362 USD
CY2010Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
282518 USD
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
169198 USD
CY2011Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
408200 USD
CY2010Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
176000 USD
CY2011Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
212900 USD
CY2010Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
149000 USD
CY2011Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
22524800 USD
CY2010Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
20161000 USD
CY2011Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17816700 USD
CY2010Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17236000 USD
CY2010Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
0 USD
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
48500 USD
CY2010Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
26000 USD
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
13800 USD
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
107300 USD
CY2010Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
17000 USD
CY2011Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2317900 USD
CY2010Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5014000 USD
CY2011Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
-3774700 USD
CY2010Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0 USD
CY2011Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
-3303000 USD
CY2010Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
0 USD
CY2011Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
3774655 USD
CY2010Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
0 USD
CY2011Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
3774700 USD
CY2010Q4 us-gaap Deferred Tax Liabilities Undistributed Foreign Earnings
DeferredTaxLiabilitiesUndistributedForeignEarnings
0 USD
CY2011Q4 us-gaap Deferred Tax Liabilities Undistributed Foreign Earnings
DeferredTaxLiabilitiesUndistributedForeignEarnings
-2138500 USD
CY2010 us-gaap Depreciation
Depreciation
200000 USD
CY2011 us-gaap Depreciation
Depreciation
900000 USD
CY2011 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1440576 USD
CY2010 us-gaap Depreciation And Amortization
DepreciationAndAmortization
137807 USD
CY2011Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
474463 USD
CY2010Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2571367 USD
CY2010Q4 us-gaap Disposal Group Including Discontinued Operation Cash And Cash Equivalents
DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
7143268 USD
CY2011Q4 us-gaap Disposal Group Including Discontinued Operation Cash And Cash Equivalents
DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
8810272 USD
CY2011 us-gaap Dividends
Dividends
-11726099 USD
CY2011Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
340400 USD
CY2011Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
3000000 USD
CY2010 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2011Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-683000 USD
CY2010Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-105600 USD
CY2011 us-gaap Finite Lived Intangible Assets Future Amortization Expense
FiniteLivedIntangibleAssetsFutureAmortizationExpense
15086000 USD
CY2011Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
15769000 USD
CY2010Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
669000 USD
CY2011Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
339400 USD
CY2010 us-gaap Extraordinary Item Net Of Tax
ExtraordinaryItemNetOfTax
3908690 USD
CY2011 us-gaap Extraordinary Item Net Of Tax
ExtraordinaryItemNetOfTax
-9448388 USD
CY2011 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
46245 USD
CY2010 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
180062 USD
CY2011 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2011Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
365700 USD
CY2010Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
85400 USD
CY2011Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
15086000 USD
CY2010Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
563400 USD
CY2011 us-gaap Future Amortization Expense After Year Five
FutureAmortizationExpenseAfterYearFive
12060000 USD
CY2011 us-gaap Future Amortization Expense Year Five
FutureAmortizationExpenseYearFive
605200 USD
CY2011 us-gaap Future Amortization Expense Year Four
FutureAmortizationExpenseYearFour
605200 USD
CY2011 us-gaap Future Amortization Expense Year One
FutureAmortizationExpenseYearOne
605200 USD
CY2011 us-gaap Future Amortization Expense Year Three
FutureAmortizationExpenseYearThree
605200 USD
CY2011 us-gaap Future Amortization Expense Year Two
FutureAmortizationExpenseYearTwo
605200 USD
CY2010 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
656278 USD
CY2011 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
0 USD
CY2011 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
0 USD
CY2010 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
-3734 USD
CY2011Q4 us-gaap Goodwill
Goodwill
11117770 USD
CY2010Q4 us-gaap Goodwill
Goodwill
0 USD
CY2011Q4 us-gaap Goodwill
Goodwill
4104500 USD
CY2011Q1 us-gaap Goodwill
Goodwill
7013500 USD
CY2011 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2011 us-gaap Gross Profit
GrossProfit
1403399 USD
CY2010 us-gaap Gross Profit
GrossProfit
181146 USD
CY2011 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-34266544 USD
CY2009Q4 us-gaap Goodwill
Goodwill
558168 USD
CY2011 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
11117770 USD
CY2010 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
558168 USD
CY2010 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-25809435 USD
CY2010 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
0 USD
CY2011 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
-299789 USD
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34566333 USD
CY2010 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25809435 USD
CY2010 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.50
CY2011 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.39
CY2010 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
6412419 USD
CY2011 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-22016524 USD
CY2010 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
3908690 USD
CY2011 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
-9148599 USD
CY2010 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
2503729 USD
CY2011 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-12867925 USD
CY2010 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.05
CY2011 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.15
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2010 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2010 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0 USD
CY2011 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
2852100 USD
CY2010 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
2938600 USD
CY2011 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-72400 USD
CY2011 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-12005500 USD
CY2010 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8800300 USD
CY2010 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2509400 USD
CY2011 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2177000 USD
CY2010 us-gaap Income Taxes Paid
IncomeTaxesPaid
2056250 USD
CY2011 us-gaap Income Taxes Paid
IncomeTaxesPaid
1119500 USD
CY2010 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-59469 USD
CY2011 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
443132 USD
CY2011 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
948452 USD
CY2010 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
60593 USD
CY2011 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
647745 USD
CY2010 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
CY2011 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-53211 USD
CY2010 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
127113 USD
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
350227 USD
CY2010 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
221979 USD
CY2011 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-2596 USD
CY2010 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
2500000 USD
CY2011Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15086038 USD
CY2010Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
563368 USD
CY2011Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5700000 USD
CY2010 us-gaap Interest Expense
InterestExpense
289526 USD
CY2011 us-gaap Interest Expense
InterestExpense
2647692 USD
CY2010 us-gaap Interest Paid
InterestPaid
279596 USD
CY2011 us-gaap Interest Paid
InterestPaid
1522700 USD
CY2010 us-gaap Interest Paid Capitalized
InterestPaidCapitalized
391466 USD
CY2011 us-gaap Interest Paid Capitalized
InterestPaidCapitalized
384300 USD
CY2011Q4 us-gaap Inventory Gross
InventoryGross
600000 USD
CY2010Q4 us-gaap Inventory Gross
InventoryGross
0 USD
CY2010Q4 us-gaap Inventory Net
InventoryNet
0 USD
CY2011Q4 us-gaap Inventory Net
InventoryNet
647745 USD
CY2010Q4 us-gaap Preferred Stock Value
PreferredStockValue
100 USD
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
100 USD
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
649739 USD
CY2010Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
322535 USD
CY2011Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
178200 USD
CY2010 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
7863492 USD
CY2011 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
10266023 USD
CY2010 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
889000 USD
CY2011 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2100000 USD
CY2010Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
143024749 USD
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
155327780 USD
CY2010Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32890101 USD
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36446644 USD
CY2010Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
17114754 USD
CY2011Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
33937292 USD
CY2010Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
31397874 USD
CY2011Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
28165010 USD
CY2010Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
14260869 USD
CY2011Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
26388976 USD
CY2006Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
500000 USD
CY2010Q4 us-gaap Minority Interest
MinorityInterest
37827738 USD
CY2011Q4 us-gaap Minority Interest
MinorityInterest
18106961 USD
CY2011Q4 us-gaap Minority Interest Ownership Percentage By Parent
MinorityInterestOwnershipPercentageByParent
0.2000
CY2011 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Company</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem, Inc. (&#8220;NeoStem&#8221; or the &#8220;Company&#8221;) was incorporated under the laws of the State of Delaware in September 1980 under the name Fidelity Medical Services, Inc. The Company&#8217;s corporate headquarters are located at 420 Lexington Avenue, Suite 450, New York, NY 10170. The Company&#8217;s telephone number is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">(212) 584-4180</font><font style="font-family:inherit;font-size:10pt;"> and its website address is </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">www.neostem.com</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem, Inc. is an international biopharmaceutical company. In 2011, we operated our business in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three reportable segments</font><font style="font-family:inherit;font-size:10pt;">: (i) Cell Therapy&#160;&#8212;&#160;United States; (ii) Regenerative Medicine&#160;&#8212;&#160;China; and (iii) Pharmaceutical Manufacturing&#160;&#8212;&#160;China. Effective March 31, 2012, we committed to discontinue operations in the Regenerative Medicine - China reportable segment, and on June 18, 2012, we also announced an agreement to sell our </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">51%</font><font style="font-family:inherit;font-size:10pt;">&#160;interest in Suzhou Erye, which represented the operations in our Pharmaceutical Manufacturing - China segment. We have recast certain information to classify the results of operations, assets and liabilities of the Pharmaceutical Manufacturing - China and Regenerative Medicine - China segments as discontinued operations (see Note 11). As a result, the Company currently operates in a single reporting segment.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is focused on the development of proprietary cellular therapies in cardiovascular disease, immunology and regenerative medicine and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> The Company is also a provider of adult stem cell collection, processing and storage services in the U.S., enabling healthy individuals to donate and store their stem cells for personal therapeutic use. In addition, the Company collects and stores cord blood cells of newborns which help to ensure a supply of autologous stem cells for the child should they be needed for future medical treatment.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company strengthened its expertise in cellular therapies with its January 19, 2011 acquisition of Progenitor Cell Therapy, LLC, a Delaware limited liability company (&#8220;PCT&#8221;). PCT is engaged in a wide range of services in the cell therapy market for the treatment of human disease, including, but not limited to contract manufacturing, product and process development, regulatory consulting, product characterization and comparability, and storage, distribution, manufacturing and transportation of cell therapy products. PCT&#8217;s legacy business relationships also afford NeoStem introductions to innovative therapeutic programs.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2011, PCT&#8217;s wholly owned subsidiary, Athelos, Inc. (Athelos), acquired rights and technology for a T-cell based immunomodulatory therapeutic in exchange for an approximate </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20.00%</font><font style="font-family:inherit;font-size:10pt;"> interest in Athelos.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company further strengthened its breadth in cellular therapies through its October 17, 2011 acquisition of Amorcyte, Inc. Amorcyte is a development stage cell therapy company focusing on novel treatments for cardiovascular disease. Amorcyte&#8217;s lead product candidate is AMR-001. In January 2012, Amorcyte enrolled its first patient in the PreSERVE Phase 2 trial to investigate AMR-001&#8217;s ability to preserve heart function after a heart attack.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company views the PCT and Amorcyte acquisitions as fundamental to building a foundation in achieving its strategic mission of capturing the paradigm shift to cell therapy.</font></div></div>
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20069370 USD
CY2010 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33855450 USD
CY2011 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
17329874 USD
CY2010 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
33278849 USD
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2054580 USD
CY2010 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17105791 USD
CY2011 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-251398 USD
CY2010 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-3595359 USD
CY2010 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8476699 USD
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20927994 USD
CY2011 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-21773200 USD
CY2010 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18677063 USD
CY2010 us-gaap Net Income Loss
NetIncomeLoss
-23305706 USD
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-47134469 USD
CY2010 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23543669 USD
CY2011 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47774234 USD
CY2011 us-gaap Noncash Contribution Expense
NoncashContributionExpense
607363 USD
CY2010 us-gaap Noncash Contribution Expense
NoncashContributionExpense
0 USD
CY2010 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
44085 USD
CY2011 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-561822 USD
CY2010 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
8894062 USD
CY2010Q4 us-gaap Notes Payable Current
NotesPayableCurrent
116895 USD
CY2011Q4 us-gaap Notes Payable Current
NotesPayableCurrent
148062 USD
CY2010 us-gaap Operating Expenses
OperatingExpenses
26034666 USD
CY2011 us-gaap Operating Expenses
OperatingExpenses
35407910 USD
CY2010 us-gaap Operating Income Loss
OperatingIncomeLoss
-25853520 USD
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-34004511 USD
CY2011Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
4214900 USD
CY2011Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1407800 USD
CY2011Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
563900 USD
CY2011Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
553700 USD
CY2011Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
563600 USD
CY2011Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
832700 USD
CY2011Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
293200 USD
CY2011Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
47427300 USD
CY2011 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
As of December 31, 2011 the Company has lost $25,994,800 or $8,838,200 in tax benefits, of net operating losses applicable to Federal income taxes which expired due to these limitations and expiration of net operating loss carryforwards
CY2011Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
654100 USD
CY2010Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
635000 USD
CY2011Q1 us-gaap Other Assets Current
OtherAssetsCurrent
166200 USD
CY2010Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2798077 USD
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3326938 USD
CY2011Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
581900 USD
CY2011 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Period Increase Decrease
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
2596987 USD
CY2010 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Period Increase Decrease
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
2835570 USD
CY2010 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2835570 USD
CY2011 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2596987 USD
CY2010 us-gaap Other Comprehensive Income Loss Net Of Tax Period Increase Decrease
OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease
2835570 USD
CY2011 us-gaap Other Comprehensive Income Loss Net Of Tax Period Increase Decrease
OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease
2596987 USD
CY2011Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
540500 USD
CY2011 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2085870 USD
CY2010 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
333611 USD
CY2011 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-561822 USD
CY2010 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
44085 USD
CY2010 us-gaap Payments For Repurchase Of Preferred Stock And Preference Stock
PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
0 USD
CY2011 us-gaap Payments For Repurchase Of Preferred Stock And Preference Stock
PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
-650000 USD
CY2011 us-gaap Payments Of Dividends
PaymentsOfDividends
0 USD
CY2010 us-gaap Payments Of Dividends
PaymentsOfDividends
-222924 USD
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
574857 USD
CY2010 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1095359 USD
CY2011 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
639765 USD
CY2010 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
237963 USD
CY2011 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
639765 USD
CY2010 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
237963 USD
CY2010Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2011 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 USD
CY2011 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2250000 USD
CY2010Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2010Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10000 shares
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10000 shares
CY2010Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10000 shares
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10000 shares
CY2010 us-gaap Profit Loss
ProfitLoss
-19397016 USD
CY2010Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
804600 USD
CY2011Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12884000 USD
CY2010Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
435496 USD
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11616053 USD
CY2011Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11755000 USD
CY2011 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
21152682 USD
CY2010 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
21212974 USD
CY2011 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
149766 USD
CY2010 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
431520 USD
CY2010 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
175992 USD
CY2011 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 USD
CY2011 us-gaap Proceeds From Repurchase Of Redeemable Preferred Stock
ProceedsFromRepurchaseOfRedeemablePreferredStock
2500000 USD
CY2011 us-gaap Profit Loss
ProfitLoss
-56582857 USD
CY2011Q1 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
3000000 USD
CY2011 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
-180132 USD
CY2010 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
-314625 USD
CY2010 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 USD
CY2011 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
-3000000 USD
CY2011 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
-149542 USD
CY2010 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
0 USD
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7720748 USD
CY2010 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6008285 USD
CY2011 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
1150000 USD
CY2010 us-gaap Restatement Of Prior Year Income Net Of Tax
RestatementOfPriorYearIncomeNetOfTax
-413600 USD
CY2011 us-gaap Restatement Of Prior Year Income Net Of Tax
RestatementOfPriorYearIncomeNetOfTax
1367300 USD
CY2010Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95320620 USD
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-143094854 USD
CY2010 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
CY2010 us-gaap Revenues
Revenues
181146 USD
CY2011 us-gaap Revenues
Revenues
10050086 USD
CY2012Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1040000 shares
CY2010Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
0 USD
CY2011Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
3635061 USD
CY2010 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19468213 USD
CY2011 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
27687162 USD
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
9555631 shares
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
1.82
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm
6.7
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
15043505 shares
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.68
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
7.3
CY2011Q4 us-gaap Shares Issued
SharesIssued
5157732 shares
CY2011 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
3467000 shares
CY2010 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
339000 shares
CY2010 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
13720048 USD
CY2011 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
21152682 USD
CY2010 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
21425538 USD
CY2011 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
3580600 USD
CY2010 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
569500 USD
CY2011 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
10266023 USD
CY2010 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7564993 USD
CY2011 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7100 USD
CY2010 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
140100 USD
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
48659881 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
62025557 USD
CY2011Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
80132518 USD
CY2010Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
86487619 USD
CY2009Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
57832377 USD
CY2011Q4 us-gaap Temporary Equity Carrying Amount
TemporaryEquityCarryingAmount
4811326 USD
CY2010Q4 us-gaap Temporary Equity Carrying Amount
TemporaryEquityCarryingAmount
6532275 USD
CY2010Q4 us-gaap Temporary Equity Liquidation Preference Per Share
TemporaryEquityLiquidationPreferencePerShare
1
CY2011Q4 us-gaap Temporary Equity Liquidation Preference Per Share
TemporaryEquityLiquidationPreferencePerShare
1
CY2011Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10582011 shares
CY2010Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10582011 shares
CY2011Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
6662748 shares
CY2010Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
10582011 shares
CY2011Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
6662748 shares
CY2010Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
10582011 shares
CY2010Q4 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
6532275 USD
CY2011Q4 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
4811326 USD
CY2010 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
-656278 USD
CY2010 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-138325 USD
CY2011 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
2096904 USD
CY2011 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.</font></div></div>
CY2011Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
-20702900 USD
CY2010Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
-20081000 USD
CY2011Q4 nbs Aggregate Intrinsic Value Warrants Outstanding
AggregateIntrinsicValueWarrantsOutstanding
0 USD
CY2011Q3 nbs Bank Deposit Freeze
BankDepositFreeze
7900000 USD
CY2011 nbs Bank Deposit Freeze
BankDepositFreeze
2460000 USD
CY2010 nbs Clinical Services Reimbursement
ClinicalServicesReimbursement
0 USD
CY2011 nbs Clinical Services Reimbursement
ClinicalServicesReimbursement
2600000 USD
CY2010 nbs Common Stock Issued To Acquire Businesses
CommonStockIssuedToAcquireBusinesses
0 USD
CY2009Q4 nbs Common Stock Warrants Shares
CommonStockWarrantsShares
19838802 shares
CY2011Q4 nbs Common Stock Warrants Shares
CommonStockWarrantsShares
37389825 shares
CY2010Q4 nbs Common Stock Warrants Shares
CommonStockWarrantsShares
21843507 shares
CY2011 nbs Contributions From Noncontrolling Interests
ContributionsFromNoncontrollingInterests
1150000 USD
CY2011Q4 nbs Decrease In Fair Value Of Embeded Derivatives
DecreaseInFairValueOfEmbededDerivatives
1900000 USD
CY2011Q4 nbs Decrease In Fair Value Of Warrant Derivative
DecreaseInFairValueOfWarrantDerivative
193000 USD
CY2011Q4 nbs Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
0 USD
CY2010Q4 nbs Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
164000 USD
CY2011Q4 nbs Deferred Tax Liabilities Accumulated Depreciation
DeferredTaxLiabilitiesAccumulatedDepreciation
-155100 USD
CY2010Q4 nbs Deferred Tax Liabilities Accumulated Depreciation
DeferredTaxLiabilitiesAccumulatedDepreciation
-80000 USD
CY2011 nbs Dividend On Preferred Stock Shares Of Common Stock Issuable
DividendOnPreferredStockSharesOfCommonStockIssuable
748900 USD
CY2010 nbs Dividend On Preferred Stock Shares Of Common Stock Issuable
DividendOnPreferredStockSharesOfCommonStockIssuable
0 USD
CY2010 nbs Dividends Preferred Stock Series C
DividendsPreferredStockSeriesC
-153469 USD
CY2010 nbs Dividends Preferred Stock Series E
DividendsPreferredStockSeriesE
-84494 USD
CY2011Q4 nbs In Process Rd
InProcessRd
9400000 USD
CY2011 nbs Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
-486952 USD
CY2010 nbs Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
-1004593 USD
CY2011 nbs Issuance Of Common Stock In Connection With Preferred Stock Settlement Value
IssuanceOfCommonStockInConnectionWithPreferredStockSettlementValue
3620300 USD
CY2011 nbs Issuance Of Common Stock In Exchange For Convertible Preferred Stock
IssuanceOfCommonStockInExchangeForConvertiblePreferredStock
3511200 USD
CY2010 nbs Issuance Of Common Stock In Exchange For Convertible Preferred Stock
IssuanceOfCommonStockInExchangeForConvertiblePreferredStock
0 USD
CY2011Q1 nbs Mortgages Payable
MortgagesPayable
3784600 USD
CY2011 nbs Notes Payable Insurance
NotesPayableInsurance
148100 USD
CY2010 nbs Notes Payable Insurance
NotesPayableInsurance
116895 USD
CY2011Q4 nbs Other Accrued Taxes
OtherAccruedTaxes
70400 USD
CY2010Q4 nbs Other Accrued Taxes
OtherAccruedTaxes
0 USD
CY2010 nbs Permanent Non Deductible Expenses For Us Taxes
PermanentNonDeductibleExpensesForUSTaxes
1838100 USD
CY2011 nbs Permanent Non Deductible Expenses For Us Taxes
PermanentNonDeductibleExpensesForUSTaxes
5907300 USD
CY2010Q4 nbs Preferred Stock Shares Designated
PreferredStockSharesDesignated
825000 shares
CY2011Q4 nbs Preferred Stock Shares Designated
PreferredStockSharesDesignated
825000 shares
CY2011 nbs Proceeds From Stock Option And Warrant Excercises
ProceedsFromStockOptionAndWarrantExcercises
7100 USD
CY2010 nbs Proceeds From Stock Option And Warrant Excercises
ProceedsFromStockOptionAndWarrantExcercises
3101850 USD
CY2011 nbs Provision For Reduction Of Doubtful Accounts
ProvisionForReductionOfDoubtfulAccounts
87773 USD
CY2010 nbs Provision For Reduction Of Doubtful Accounts
ProvisionForReductionOfDoubtfulAccounts
-39536 USD
CY2011 nbs Stock Issued During Period Value Amorcyte Merger
StockIssuedDuringPeriodValueAmorcyteMerger
5353400 USD
CY2011 nbs Stock Issued During Period Value Charitable Contribution
StockIssuedDuringPeriodValueCharitableContribution
607363 USD
CY2010 nbs Stock Issued During Period Value Charitable Contribution
StockIssuedDuringPeriodValueCharitableContribution
298500 USD
CY2011 nbs Stock Issued During Period Value Pct Merger
StockIssuedDuringPeriodValuePctMerger
17200000 USD
CY2010 nbs Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
2961750 USD
CY2012Q2 nbs Stock Option Cancelled
StockOptionCancelled
1170000 shares
CY2011 nbs Supplemental Deferred Financing Costs
SupplementalDeferredFinancingCosts
0 USD
CY2010 nbs Supplemental Deferred Financing Costs
SupplementalDeferredFinancingCosts
33355 USD
CY2011 nbs Supplemental Dividends From Subsidiaries
SupplementalDividendsFromSubsidiaries
11726100 USD
CY2010 nbs Supplemental Dividends From Subsidiaries
SupplementalDividendsFromSubsidiaries
0 USD
CY2010 nbs Supplemental Property And Equipment Net
SupplementalPropertyAndEquipmentNet
2443958 USD
CY2011 nbs Supplemental Property And Equipment Net
SupplementalPropertyAndEquipmentNet
0 USD
CY2011Q4 nbs Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
5324300 USD
CY2011Q4 nbs Warrants And Rights Exercisable
WarrantsAndRightsExercisable
35931825 shares
CY2011 nbs Warrants Canceled
WarrantsCanceled
0 shares
CY2010 nbs Warrants Canceled
WarrantsCanceled
-150000 shares
CY2012Q2 nbs Warrants Canceled
WarrantsCanceled
640000 shares
CY2011Q4 nbs Warrants Exercisable Weighted Average Exercise Price
WarrantsExercisableWeightedAverageExercisePrice
2.24
CY2011Q4 nbs Warrants Exercisable Weighted Average Remaining Contractual Term
WarrantsExercisableWeightedAverageRemainingContractualTerm
3.8
CY2011 nbs Warrants Exercised
WarrantsExercised
0 shares
CY2010 nbs Warrants Exercised
WarrantsExercised
-2025000 shares
CY2011 nbs Warrants Expired
WarrantsExpired
-448000 shares
CY2010 nbs Warrants Expired
WarrantsExpired
-1613191 shares
CY2011 nbs Warrants Granted
WarrantsGranted
15993947 shares
CY2010 nbs Warrants Granted
WarrantsGranted
5792896 shares
CY2010 nbs Warrants Issued During Period
WarrantsIssuedDuringPeriod
627000000 shares
CY2011 nbs Warrants Issued During Period
WarrantsIssuedDuringPeriod
670000000 shares
CY2010 nbs Warrants Issued During Period Value
WarrantsIssuedDuringPeriodValue
772200 USD
CY2011 nbs Warrants Issued During Period Value
WarrantsIssuedDuringPeriodValue
495100 USD
CY2011Q4 nbs Warrants Outstanding Weighted Average Exercise Price
WarrantsOutstandingWeightedAverageExercisePrice
2.35
CY2011Q4 nbs Warrants Outstanding Weighted Average Remaining Contractual Term
WarrantsOutstandingWeightedAverageRemainingContractualTerm
3.9
CY2010 nbs Weighted Average Estimated Fair Value Of Restricted Stock
WeightedAverageEstimatedFairValueOfRestrictedStock
1.68
CY2011 nbs Weighted Average Estimated Fair Value Of Restricted Stock
WeightedAverageEstimatedFairValueOfRestrictedStock
1.03
CY2010 nbs Weighted Average Exercise Price Warrants Canceled
WeightedAverageExercisePriceWarrantsCanceled
2.78
CY2011 nbs Weighted Average Exercise Price Warrants Canceled
WeightedAverageExercisePriceWarrantsCanceled
0
CY2010 nbs Weighted Average Exercise Price Warrants Exercised
WeightedAverageExercisePriceWarrantsExercised
1.46
CY2011 nbs Weighted Average Exercise Price Warrants Exercised
WeightedAverageExercisePriceWarrantsExercised
0
CY2011 nbs Weighted Average Exercise Price Warrants Expired
WeightedAverageExercisePriceWarrantsExpired
6.18
CY2010 nbs Weighted Average Exercise Price Warrants Expired
WeightedAverageExercisePriceWarrantsExpired
6.54
CY2011 nbs Weighted Average Exercise Price Warrants Granted
WeightedAverageExercisePriceWarrantsGranted
2.09
CY2010 nbs Weighted Average Exercise Price Warrants Granted
WeightedAverageExercisePriceWarrantsGranted
1.99
CY2010Q4 nbs Weighted Average Exercise Price Warrants Outstanding
WeightedAverageExercisePriceWarrantsOutstanding
2.62
CY2011Q4 nbs Weighted Average Exercise Price Warrants Outstanding
WeightedAverageExercisePriceWarrantsOutstanding
2.35
CY2009Q4 nbs Weighted Average Exercise Price Warrants Outstanding
WeightedAverageExercisePriceWarrantsOutstanding
3
CY2011Q4 nbs Weighted Average Remaining Contractual Term Warrants Outstanding
WeightedAverageRemainingContractualTermWarrantsOutstanding
3.87
CY2011 nbs Weightedaveragenumberbasicdilutedsharesoutstanding
Weightedaveragenumberbasicdilutedsharesoutstanding
88598696 shares
CY2010 nbs Weightedaveragenumberbasicdilutedsharesoutstanding
Weightedaveragenumberbasicdilutedsharesoutstanding
51632417 shares
CY2011 nbs Writedown Of Net Operating Losses
WritedownOfNetOperatingLosses
0 USD
CY2010 nbs Writedown Of Net Operating Losses
WritedownOfNetOperatingLosses
1932600 USD
CY2011 dei Amendment Flag
AmendmentFlag
false
CY2011 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2011 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2011 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2011
CY2011 dei Document Period End Date
DocumentPeriodEndDate
2011-12-31
CY2011 dei Document Type
DocumentType
8-K
CY2011 dei Entity Central Index Key
EntityCentralIndexKey
0000320017
CY2012Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
114348438 shares
CY2011 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2011 dei Entity Registrant Name
EntityRegistrantName
NEOSTEM, INC.

Files In Submission

Name View Source Status
0001445305-12-002656-index-headers.html Edgar Link pending
0001445305-12-002656-index.html Edgar Link pending
0001445305-12-002656.txt Edgar Link pending
0001445305-12-002656-xbrl.zip Edgar Link pending
exhibit-231.htm Edgar Link pending
exhibit-232.htm Edgar Link pending
exhibit-991.htm Edgar Link pending
exhibit-992.htm Edgar Link pending
exhibit9932q2012pressrelea.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
form8k.htm Edgar Link pending
nbs-20120808.xml Edgar Link completed
nbs-20120808.xsd Edgar Link pending
nbs-20120808_cal.xml Edgar Link unprocessable
nbs-20120808_def.xml Edgar Link unprocessable
nbs-20120808_lab.xml Edgar Link unprocessable
nbs-20120808_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending